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Introduction
============

Severe aortic stenosis (AS) is associated with significant functional impairment in the elderly population with poor prognosis \[[@REF1]\]. Only one-third of symptomatic adults with severe AS can be candidates for high-risk surgical interventions due to their underlying comorbidities \[[@REF2]\]. Therefore, in recent years, the use of transcatheter aortic valve replacement (TAVR) has become standard of care, with an increase in the number of implants per million adults from 24.8 in 2012 to 63.2 in 2014 compared to surgical aortic valve replacement (SAVR) in intermediate and high surgical risk populations \[[@REF3]-[@REF6]\]. This trend is primarily due to a decreased risk of mortality with TAVR compared to SAVR and a significantly lower risk of acute kidney injury (AKI) with TAVR compared to SAVR \[[@REF7],[@REF8]\]. Two recently published non-inferiority trials comparing TAVR to SAVR in the low-risk patient population also reported significantly reduced events of AKI in the TAVR arm \[[@REF7],[@REF9]\]. We recently published a meta-analysis comparing TAVR with SAVR in patients with severe AS and reported their renal outcomes \[[@REF10]\]. This is an updated meta-analysis of all the available randomized controlled trials (RCTs) to report AKI at 30 days and one year, and AKI requiring renal transplant in low-, intermediate-, and high-risk candidates. The results of this analysis were also presented at the American Heart Association meeting in 2019 (Paper presentation: Siddiqui WJ, Mazhar R, Abbas R, Sadaf M, Zain M, Omer Z, Al-Saghir Y. Abstract 15718: Acute Kidney Injury After Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement - A Meta-Analysis. Meeting of the American Heart Association; 2019).

Materials and methods
=====================

Data sources and search strategy

We conducted our systematic review following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines \[[@REF11]\]. We searched for RCTs using MEDLINE, PUBMED, and Google Scholar databases comparing TAVR to SAVR for the treatment of AS using following keywords and MeSH terms: "aortic stenosis, surgical aortic valve replacement, transcatheter aortic valve replacement, transcatheter aortic valve implantation, AS, SAVR, TAVR, and TAVI" from inception to April 6, 2019. Our search strategy included (aortic stenosis) OR (AS) AND (SAVR) OR (surgical aortic valve replacement) AND (TAVR) OR (transcatheter aortic valve replacement) OR (TAVI) OR (transcatheter aortic valve implantation). We used Boolean Operators "AND" and "OR" to combine the search terms. After identifying duplications, a total of 291 studies were finally identified.

Study selection

Three reviewers (W.J.S., R.M., and R.A.) reviewed the titles and abstracts, and they excluded 265 studies that failed to meet our inclusion criteria. We assessed the full text of 26 studies; 18 were excluded as they lacked the primary outcome of interest, or since they were sub-studies of original trials. We included eight RCTs for our systematic review and meta-analysis, which compared TAVR outcomes to SAVR outcomes (Figure [1](#FIG1){ref-type="fig"}).
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Inclusion criteria

The inclusion criteria were as follows: the study should be a prospective RCT comparing TAVR to SAVR for severe AS; patients should be of age ≥18 years; the study sample size must consist of at least 50 patients; AKI should be at least one among the outcomes reported. The primary endpoints we analyzed consisted of AKIs at 30 days, renal injury at one year, and need for renal replacement therapy.

The secondary endpoints we analyzed consisted of all-cause mortality at 30 days and one year, mortality secondary to cardiovascular causes at 30 days and one year, rehospitalizations at 30 days and one year, stroke or transient ischemic attacks at 30 days and one year, incidence of myocardial infarction (MI), postprocedure-related major bleeding, new-onset atrial fibrillation, heart block requiring permanent pacemaker placement, vascular complications, and incidence of valve endocarditis.

Data extraction and quality assessment 

The reviewers W.J.S., R.M., and R.A. extracted data into predefined fields on a Microsoft Excel (Microsoft, Redmond, WA) sheet for baseline characteristics and study outcomes. W.J.S. cross-checked the data and made the necessary corrections. All three reviewers discussed the revisions and reached a consensus on the final entry.

Data synthesis and analysis

Statistical Method

We used the random-effects model and the Mantel-Haenszel method in Review Manager (RevMan) Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014, Copenhagen) for dichotomous data to calculate the risk and odds ratio (OR) and 95% confidence intervals (CI). We reported results as forest plots. We used GraphPad Online (GraphPad Software, La Jolla, CA) to calculate Chi^2^ to compare the baseline characteristics of two groups. A two-sided p-value of \<0.05 was considered statistically significant.

Heterogeneity

We used I^2^ statistics to calculate the heterogeneity. We considered I^2^of \>50% as substantial heterogeneity, as explained in the Cochrane Handbook for Systematic Reviews \[[@REF12]\]. We performed a sensitivity analysis for considerable heterogeneity.

Results
=======

We included eight RCTs with 7,889 patients (4,017 with TAVR and 3,872 with SAVR) in our analysis. Baseline characteristics and salient features of the studies are summarized in Table [1](#TAB1){ref-type="table"} \[[@REF5],[@REF6],[@REF7],[@REF9],[@REF13]-[@REF16]\]. Primary and secondary outcomes are summarized in Table [2](#TAB2){ref-type="table"}.

###### Summary of baseline characteristics and salient features of the studies

TAVR: transcatheter aortic valve replacement; SAVR: surgical aortic valve replacement; NEJM: New England Journal of Medicine; JACC: Journal of American College of Cardiology; RCT: randomized controlled trial; N/A: not available; SD: standard deviation

  --------------------------------------------------------------------- ---------------------------------- ------------------------------- ------------------------------------ --------------------------------- ----------------------------------------------- ------------------------------------ -------------------------------- ------------------------------- ----------- ------------ ------------- ------------- ------------- ------------- ----------- -----------
  Characteristics                                                       Reardon et al., 2017 \[[@REF6]\]   Leon et al., 2016 \[[@REF5]\]   Thyregod et al., 2015 \[[@REF13]\]   Adams et al., 2014 \[[@REF14]\]   Nielsen et al., 2012 \[[@REF15]\]               Smith et al., 2011 \[[@REF16]\]      Popma et al., 2019 \[[@REF7]\]   Mack et al., 2019 \[[@REF9]\]                                                                                                
  Journal                                                               NEJM                               NEJM                            JACC                                 NEJM                              Eurointervention                                NEJM                                 NEJM                             NEJM                                                                                                                         
  Design                                                                Multicenter, prospective RCT       Multicenter, prospective RCT    Multicenter, prospective RCT         Multicenter, prospective RCT      Multicenter, prospective RCT                    Multicenter, prospective RCT         Multicenter, prospective RCT     Multicenter, prospective RCT                                                                                                 
  Population                                                            Intermediate risk                  Low--intermediate risk          Low 82%, intermediate 18% risk       High risk                         Low--intermediate risk, requested from ILLiad   High risk for surgery (inoperable)   Low risk for surgery             Low risk for surgery                                                                                                         
                                                                        TAVR                               SAVR                            TAVR                                 SAVR                              TAVR                                            SAVR                                 TAVR                             SAVR                            TAVR        SAVR         TAVR          SAVR          TAVR          SAVR          TAVR        SAVR
                                                                        n = 864                            n = 796                         n = 1,011                            n = 1,021                         n = 145                                         n = 135                              n = 394                          n = 401                         n = 34      n = 36       n = 348       n = 351       n = 725       n = 678       n = 496     n = 454
  Age, years, mean±SD                                                   79.9±6.2                           79.7±6.1                        81.5±6.7                             81.7±6.7                          79.2±4.9                                        79.0±4.7                             83.2±7.1                         83.5±6.3                        80.0±3.6    82.0±4.4     83.6±6.8      84.5±6.4      74.1±5.8      73.6±5.9      73.3±5.8    73.6±6.1
  Male, n (%)                                                           498 (57.6%)                        438 (55.0%)                     548 (54.2%)                          560 (54.8%)                       78 (53.8%)                                      71 (52.6%)                           N/A                              N/A                             9 (26.5%)   12 (33.3%)   201 (57.8%)   198 (56.7%)   464 (64%)     449 (66.2%)   335±67.5    323±71.1
  Logistic EuroSCORE, mean±SD                                           11.9±7.6                           11.6±8.0                        N/A                                  N/A                               8.4±4.0                                         8.9±5.5                              17.6±13.0                        18.4±12.8                       9.4±3.9     10.3±5.8     29.3±16.5     29.2±15.6     N/A           N/A           1.5±1.2     1.5±0.9
  Diabetes mellitus, n                                                  295                                277                             381                                  349                               26                                              28                                   136                              172                             1           3            N/A           N/A           228           207           155         137
  Hypertension, n                                                       801                                719                             N/A                                  N/A                               103                                             103                                  375                              386                             N/A         N/A          N/A           N/A           614           559           N/A         N/A
  Peripheral vascular disease, n                                        266                                238                             282                                  336                               6                                               9                                    163                              169                             2           3            148           142           54            56            34          33
  Cerebral vascular disease, n                                          N/A                                N/A                             325                                  317                               24                                              22                                   N/A                              N/A                             1           1            95            87            74            80            N/A         N/A
  Stroke, n                                                             57                                 57                              N/A                                  N/A                               N/A                                             N/A                                  51                               53                              N/A         N/A          N/A           N/A           N/A           N/A           17          23
  Transient ischemic attack, n                                          58                                 46                              N/A                                  N/A                               N/A                                             N/A                                  50                               51                              N/A         N/A          N/A           N/A           N/A           N/A           N/A         N/A
  Coronary artery disease, n                                            541                                511                             700                                  679                               N/A                                             N/A                                  297                              306                             N/A         N/A          260           266           N/A           N/A           137         127
  Myocardial infarction, n                                              125                                111                             185                                  179                               8                                               6                                    101                              98                              N/A         N/A          92            103           48            33            28          26
  Coronary artery bypass graft, n                                       138                                137                             239                                  261                               N/A                                             N/A                                  117                              121                             N/A         N/A          147           152           18            14            N/A         N/A
  Percutaneous coronary intervention, n                                 184                                169                             274                                  282                               11                                              12                                   133                              152                             N/A         N/A          116           110           103           87            N/A         N/A
  Pacemaker, n                                                          84                                 72                              118                                  123                               5                                               6                                    92                               83                              N/A         N/A          69            76            23            26            12          13
  Congestive heart failure, n                                           824                                769                             N/A                                  N/A                               N/A                                             N/A                                  376                              387                             N/A         N/A          N/A           N/A           N/A           N/A           N/A         N/A
  Balloon valvuloplasty, n (%)                                          N/A                                N/A                             51 (5.0%)                            50 (4.9%)                         N/A                                             N/A                                  N/A                              N/A                             N/A         N/A          46 (13.4%)    35 (10.2%)    N/A           N/A           N/A         N/A
  Atrial fibrillation/atrial flutter, n                                 243                                211                             313                                  359                               40                                              34                                   161                              190                             N/A         N/A          80            73            111           98            78          85
  New York Heart Association Class, n                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Class II                                                              344                                333                             N/A                                  N/A                               67                                              70                                   56                               53                              N/A         N/A          20            21            467           422           N/A         N/A
  Class III                                                             472                                411                             N/A                                  N/A                               67                                              57                                   258                              277                             N/A         N/A          328           328           181           190           155         108
  Class IV                                                              48                                 52                              N/A                                  N/A                               3                                               4                                    80                               71                              N/A         N/A          328           328           1             3                         
  Society of Thoracic Surgeons Predictive Risk of Mortality mean, ±SD   N/A                                N/A                             5.8±2.1                              5.8±1.9                           2.9±1.6                                         3.1±1.7                              7.3±3.0                          7.5±3.2                         3.1±1.5     3.4±1.2      N/A           N/A           1.9±0.7       1.9±0.7       1.9±0.7     1.9±0.6
  Society of Thoracic Surgeons Predictive Risk of Mortality mean, n     N/A                                N/A                             N/A                                  N/A                               N/A                                             N/A                                  48                               52                              N/A         N/A          N/A           N/A           N/A           N/A           N/A         N/A
  Creatinine level of \>2 mg/dl (177 µmol/lit), n (%)                   14 (1.6%)                          17 (2.1%)                       51 (5.0%)                            53 (5.2%)                         2 (1.4%)                                        1 (0.7%)                             N/A                              N/A                             1 (2.9%)    0            38 (11.1%)    24 (7.0%)     3 (0.4%)      1 (0.1%)      0.2         0.2
  Aortic valve area (cm^2^), mean±SD                                    N/A                                N/A                             0.7±0.2                              0.7±0.2                           N/A                                             N/A                                  N/A                              N/A                             0.66±0.17   0.71±0.17    0.7±0.2       0.6±0.2       0.8±0.2       0.8±0.2       0.8±0.2     0.8±0.2
  Aortic-valve gradient (mmHg), mean±SD                                 N/A                                N/A                             44.9±13.4                            44.6±12.5                         N/A                                             N/A                                  N/A                              N/A                             81±26       66±23        42.7±14.6     43.5±14.3     47±12.1       46.6±12.2     49.4±12.8   48.3±11.8
  Left ventricular ejection fraction (%), mean±SD                       N/A                                N/A                             56.2±10.8                            55.3±11.9                         N/A                                             N/A                                  N/A                              N/A                             56.5±9.7    56.3±10      52.5±13.5     53.3±12.8     61.7 (7.9%)   61.9 (7.7%)   65.7±9.0    66.2±8.6
  --------------------------------------------------------------------- ---------------------------------- ------------------------------- ------------------------------------ --------------------------------- ----------------------------------------------- ------------------------------------ -------------------------------- ------------------------------- ----------- ------------ ------------- ------------- ------------- ------------- ----------- -----------

###### Primary and secondary outcomes

TAVR: transcatheter aortic valve replacement; SAVR: surgical aortic valve replacement; CV: cardiovascular; CI: confidence interval

  -------------------------------------------------------------------- --------- --------- ----------------- ------------ ----------- ------
  Outcome                                                              TAVR, n   SAVR, n   Effect estimate   95% CI       P-value     I^2^
  Primary outcomes                                                                                                                    
  Acute kidney injury at 30 days                                       66        160       0.38              0.28--0.51   \<0.00001   0%
  Acute kidney injury at 1 year                                        74        129       0.57              0.32--1.01   0.05        69%
  Acute kidney injury requiring renal replacement therapy              20        23        0.87              0.47--1.62   0.67        0%
  Secondary outcomes                                                                                                                  
  Cerebral vascular accident or transient ischemic attack at 30 days   179       197       0.91              0.65--1.25   0.55        43%
  Cerebral vascular accident or transient ischemic attack at 1 year    266       283       0.94              0.72--1.24   0.68        51%
  Major bleeding                                                       496       954       0.46              0.26--0.81   0.008       95%
  Major vascular complications                                         170       61        2.77              1.52--5.06   0.0009      70%
  Myocardial infarction                                                41        44        0.87              0.56--1.34   0.52        0%
  Mortality from any cause at 30 days                                  94        112       0.8               0.59--1.08   0.15        5%
  Mortality from any cause at 1 year                                   349       375       0.89              0.76--1.04   0.15        0%
  Mortality from any CV cause at 30 days                               71        74        0.94              0.68--1.31   0.73        0%
  Mortality from any CV cause at 1 year                                180       198       0.88              0.7--1.1     0.25        8%
  New-onset atrial fibrillation                                        343       1,009     0.24              0.16--0.37   \<0.00001   89%
  Need for permanent pacemaker                                         555       179       3.03              1.77--5.2    \<0.0001    87%
  Rehospitalizations at 30 days                                        66        91        0.67              0.46--0.98   0.04        23%
  Rehospitalizations at 1 year                                         190       198       0.85              0.54--1.33   0.47        78%
  Valve endocarditis                                                   8         10        0.77              0.28--2.06   0.6         0%
  -------------------------------------------------------------------- --------- --------- ----------------- ------------ ----------- ------

Primary outcomes

We noted a significant reduction in AKIs at 30 days after TAVR compared with SAVR, (n = 66 vs. n = 160, respectively; OR = 0.38, 95% CI = 0.28-0.51; p = \<0.00001, I^2^ = 0%) (Figure [2](#FIG2){ref-type="fig"}) \[[@REF5],[@REF6],[@REF7],[@REF9],[@REF13]-[@REF16]\]. We also noted a reduction in the trend of persistent renal injury at one year after TAVR compared to SAVR (n = 74 vs. n = 129, respectively; OR = 0.57, 95% CI = 0.32-1.01; p = 0.05, I^2^ = 69%). With sensitivity analysis without Smith et al., results became significant favoring TAVR (OR = 0.45, CI = 0.28-0.73, p = 0.001, I^2^ = 49%) (Figure [3](#FIG3){ref-type="fig"}) \[[@REF5],[@REF7],[@REF9],[@REF14],[@REF16]\]. There was no difference in the need for renal replacement therapy (RRT) in the TAVR group compared to the SAVR group (n = 20 vs. n = 23, respectively; OR = 0.87, 95% CI = 0.47-1.62, p = 0.67, I^2^= 0%) (Figure [4](#FIG4){ref-type="fig"}) \[[@REF9],[@REF15],[@REF16]\].
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Secondary outcomes

As noted in Table [2](#TAB2){ref-type="table"}, we found no significant differences between TAVR and SAVR in many secondary outcomes with several notable exceptions. TAVR yielded significantly reduced rehospitalizations at 30 days compared with SAVR (n = 66 vs. n = 91, respectively; OR = 0.67, 95% CI = 0.46-0.98; p = 0.04, I^2^ = 23%). The TAVR approach had significantly reduced postprocedure-related major bleeding compared with the SAVR approach (n = 496 vs. n = 954, respectively; OR = 0.46, 95% CI = 0.26-0.81; p = 0.008, I^2^ = 95%) and incidence of new-onset atrial fibrillation (n = 343 vs. n = 1009, respectively; OR = 0.24, 95% CI = 0.16-0.37; p = \<0.00001, I^2^ = 89%). TAVR patients required more permanent pacemaker placement than SAVR patients (n = 555 vs. n = 179, respectively; OR = 3.03, 95% CI = 1.77-5.2; p = \<0.0001, I^2^ = 87%) and had a higher incidence of vascular complications (n = 170 vs. n = 61, respectively; OR = 2.77, 95% CI = 1.52-5.06, p = 0.0009, I^2^ = 70%).

Discussion
==========

AKI remains a significant concern following TAVR and SAVR. Our meta-analysis showed that the patients who underwent TAVR had significantly better renal outcomes at 30 days compared to patients who underwent SAVR. However, we observed no difference in TAVR or SAVR in terms of the persistent renal injury and need for RRT at one year. One study showed that improvement in stroke volume and cardiac output after SAVR or TAVR increases the level of renal perfusion, which itself favors the improved renal function and supports our study's results. However, the study further claims that patients with baseline chronic kidney disease (CKD) are at increased risk of persistent renal injury and need RRT after aortic valve replacement \[[@REF17]\]. One retrospective study concluded that as the estimated glomerular filtration rate drops below 30 ml/min/m2, the need for RRT is increased to one in six patients with mortality increasing to one in three in CKD-4 patients at one year \[[@REF18]\]. A study done in the UK about the post-TAVR need for RRT has suggested that the requirement for RRT depends not only on baseline renal function but a compromised left ventricular function, history of diabetes mellitus, post-procedural paravalvular leakage, type of valve used, and route of peripheral access other than transfemoral access during TAVR \[[@REF19]\]. We also know that the use of cardiopulmonary bypass with extracorporeal circulation during SAVR is a risk factor for patients with AKI or long-standing CKD, and only three RCTs had persistent renal failure at one year, and two RCTs had the need for RRT at the one-year interval. Hence, we think that these results are biased as the data regarding the potential cases with the possibility of developing CKD and requiring RRT after a year of AVR are unavailable. Therefore, more data from RCTs documenting the baseline renal function as well as data from the renal standpoint at a one-year interval are mandatory to evaluate this trend better.

The data regarding the specific intervention to prevent AKI following TAVR are also scarce. It was interesting to see the results from the Prevention of Serious Adverse Events Following Angiography (PRESERVE) trial, which enrolled over 5,000 patients with CKD of 3b or worse without diabetes, or those with CKD of 3a or worse with diabetes. Patients underwent either a coronary or noncoronary angiogram. The administration of normal saline, sodium bicarbonate, or acetylcysteine over placebo failed to demonstrate any benefit \[[@REF20]\]. As the contrast administration is the primary risk factor associated with AKI following TAVR, especially in patients with underlying CKD, Chatani et al. found no advantage of using iso-osmolar contrast agent compared with a low-osmolar agent during TAVI for preventing post-TAVR AKI \[[@REF21]\]. Barbanti et al.'s trial is the only trial done in patients undergoing TAVR to demonstrate the benefit of forced diuresis using the RenalGuard system (RenalGuard Solutions, Inc., Milford, MA) with furosemide and saline over standard saline alone. The forced diuresis technique can be considered in future RCTs, with the principal focus on patients with underlying CKD \[[@REF22]\].

In our study, there was no significant difference between the TAVR and SAVR subgroups in terms of risk of stroke, transient ischemic attack, MI, and mortality from any cause as well as cardiovascular causes at 30 days and one year. However, we saw a reduction in the incidence of major bleeding, major vascular complications, rehospitalizations at 30 days, and new-onset atrial fibrillation in the TAVI group. Although studies have consistently shown a lower incidence of new-onset atrial fibrillation in patients who underwent TAVR compared with SAVR, the rate of permanence remains unknown. Amat-Santos et al. found that the incidence of new-onset atrial fibrillation and stroke increased following TAVR with large atrial size and when opting for the transapical TAVR route \[[@REF23]\]. Tarantini et al. reported an association of post-TAVR new-onset atrial fibrillation with a higher incidence of stroke rates at long-term follow-up \[[@REF24]\]. A study by Holmes et al., which studied data from the TAVR therapies registry, reported the incidence of new-onset atrial fibrillation following TAVR to be 6.3% \[[@REF25]\]. The incidence of permanent pacemaker (PPM) installation rates was common after TAVR. Conduction disturbances requiring PPM following TAVR are a known complication and appear to be unrelated to valve type \[[@REF26]-[@REF28]\]. Factors of post-TAVR PPM implantation incidence can be predicted by pre-existing right bundle branch block (RBBB), the prosthesis to left ventricular outflow tract diameter ratio, and the left ventricular end-diastolic diameter with a longer duration of hospital stay.

From our review and analysis, we propose an algorithm for deciding between TAVR or SAVR in patients with severe AS according to baseline CKD and electrocardiographic (EKG) changes (presented in Figure 5). It is imperative to differentiate patients by surgical risk, especially those with high-risk from low-to-intermediate surgical risk patients. For patients with low-to-intermediate risk for surgery, the decision regarding TAVR or SAVR should be left to the patients themselves; however, for high surgical risk, the physician should consider TAVR along with two additional considerations. First, if the patient has underlying baseline EKG abnormalities such as heart block or RBBB, a physician should consider electrophysiology consult before TAVR for a preemptive placement of a PPM. Second, if the patient has no CKD or has CKD-1 to CKD-3, the physician should proceed with TAVR. In patients with advanced CKD-4, CKD-5, or in those already on hemodialysis, physicians should discuss the benefits and adverse outcomes of TAVR with the patient, such as worse hospital outcomes and higher incidence of mortality. The physician should also offer the patient SAVR as an alternative option.

Our analysis has several limitations. First, we included all RCTs that randomized patients with low, intermediate, and high surgical risk for SAVR. Secondly, most patients who were recruited had a stable renal function without advanced CKD. The included trials used different valves for TAVR, which makes it challenging to identify if one valve has any protective role in renal outcomes over another. Also, renal outcomes addressed by each trial were either secondary outcomes or were reported in the supplementary appendix. Finally, we had no access to the patient-level data to identify baseline renal function.

Conclusions
===========

Our analysis showed that TAVR is associated with a significant reduction in renal injury in patients compared to SAVR. Given the success associated with TAVR, novel and robust measures are needed to minimize the renal injury that is associated with poor outcomes post valve replacement.
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